December 29, 2012，Kellen Pharmaceutical issued an announcement，The Fifth Session of the Fourth Board of Directors of the Company with a full vote review and approve the "Proposal of Partial Equity of the acquisition of Lijun International Pharmaceutical (Holdings) Co., Ltd."，Coron International, a wholly -owned subsidiary of the company as the main body。This is the biggest merger and acquisition case in 2012，It is also the company to improve the antibiotic industry chain、Important measures for high -quality resources of integrated infusion and non -infusion business，It is the company to integrate industrial integration、stake online sports bettingstake sports betting appThe implementation practice of systematic promotion strategic planning，This merger implies extraordinary meaning。

    Kellen Pharmaceutical Announcement Show，All -Assets subsidiary Coron International will be transferred to Junlian Industrial Co., Ltd. and China Pharmaceutical Co., Ltd. at the price of HK $ 525 million (equivalent to RMB 426 million) in accordance with the agreement. Holdings) Co., Ltd.'s 180 million shares，The price per share is HK $ 2.9167; after the transfer of the shares of this agreement，Keron International will also purchase the total funds of Lijun International's shares through the open market and other legal methods not exceeding HK $ 1.413 billion (equivalent to RMB 1.147 billion)。After the completion of stake sports betting appstake online sports bettingLingjun International's shares in the agreement shares and the public market and other methods of Colom International，Keron International holds 30%(excluding 30%) that does not exceed Lijun International's public offering of shares，It will become the largest shareholder of Lijun International。